Barclays PLC Has $5.77 Million Holdings in Neogen Co. (NASDAQ:NEOG)

Barclays PLC boosted its holdings in Neogen Co. (NASDAQ:NEOG - Free Report) by 29.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 475,365 shares of the company's stock after buying an additional 108,612 shares during the quarter. Barclays PLC owned 0.22% of Neogen worth $5,771,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Norges Bank acquired a new stake in Neogen during the 4th quarter worth about $212,171,000. Vanguard Group Inc. raised its holdings in shares of Neogen by 9.8% during the fourth quarter. Vanguard Group Inc. now owns 21,637,251 shares of the company's stock valued at $262,676,000 after acquiring an additional 1,928,491 shares during the period. Private Advisor Group LLC lifted its position in shares of Neogen by 135.3% in the 4th quarter. Private Advisor Group LLC now owns 67,298 shares of the company's stock valued at $817,000 after acquiring an additional 38,703 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Neogen by 2.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,061,927 shares of the company's stock worth $25,032,000 after purchasing an additional 52,663 shares during the period. Finally, Pictet Asset Management Holding SA grew its position in Neogen by 26.9% during the 4th quarter. Pictet Asset Management Holding SA now owns 2,369,595 shares of the company's stock worth $28,767,000 after purchasing an additional 501,957 shares in the last quarter. Institutional investors own 96.73% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Guggenheim lowered their price target on Neogen from $15.00 to $13.00 and set a "buy" rating on the stock in a report on Thursday, April 10th. Piper Sandler lowered their price objective on shares of Neogen from $6.40 to $5.00 and set a "neutral" rating on the stock in a research report on Tuesday, April 22nd.

Neogen Stock Down 2.1 %

NEOG traded down $0.11 during trading on Tuesday, reaching $5.03. 4,687,144 shares of the stock traded hands, compared to its average volume of 2,756,044. The stock's 50-day simple moving average is $7.90 and its two-hundred day simple moving average is $11.14. The company has a debt-to-equity ratio of 0.33, a current ratio of 3.77 and a quick ratio of 2.46. Neogen Co. has a fifty-two week low of $3.87 and a fifty-two week high of $18.58. The stock has a market cap of $1.09 billion, a price-to-earnings ratio of -2.30 and a beta of 1.57.

Neogen (NASDAQ:NEOG - Get Free Report) last announced its quarterly earnings results on Wednesday, April 9th. The company reported $0.10 EPS for the quarter, missing the consensus estimate of $0.12 by ($0.02). The firm had revenue of $221.00 million during the quarter, compared to the consensus estimate of $225.27 million. Neogen had a negative net margin of 52.12% and a positive return on equity of 2.89%. The company's quarterly revenue was down 3.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.12 EPS. As a group, equities research analysts expect that Neogen Co. will post 0.38 EPS for the current year.

Insiders Place Their Bets

In related news, Director James P. Tobin purchased 10,000 shares of Neogen stock in a transaction on Tuesday, April 22nd. The stock was bought at an average price of $4.73 per share, with a total value of $47,300.00. Following the completion of the transaction, the director now directly owns 37,474 shares of the company's stock, valued at approximately $177,252.02. This represents a 36.40 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director James C. Borel acquired 35,000 shares of the stock in a transaction dated Thursday, April 24th. The shares were bought at an average cost of $4.89 per share, for a total transaction of $171,150.00. Following the acquisition, the director now owns 60,474 shares in the company, valued at $295,717.86. The trade was a 137.39 % increase in their position. The disclosure for this purchase can be found here. Insiders acquired 67,500 shares of company stock valued at $331,525 over the last ninety days. Corporate insiders own 1.13% of the company's stock.

Neogen Profile

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.